ClinicalTrials.gg
CompletedNCT04435600OptIMMize-1Updated May 20, 2025Results posted

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

A Phase 3 interventional study of Risankizumab and Ustekinumab in Psoriasis, sponsored by AbbVie. Completed at 53 sites in 7 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-05-20.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
139
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
17th of 30
139 · median 162
Started
2020
with 2 others
Phase 3
17 of 30
none open now
Registered
20th of 30
by date
Lead sponsor
24 of 30
AbbVie

Among the 30 studies testing risankizumab in Psoriasis, this one is the 17th largest by enrollment, is one of 3 that started in 2020, is one of 17 in phase 3, and was the 20th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. There is an unmet medical need for effective treatment in pediatric patients and this study is being done to evaluate risankizumab in pediatric participants with moderate to severe plaque psoriasis. This study will assess the change in disease symptoms.

Risankizumab is a drug being studied for the treatment for plaque psoriasis in pediatric participants. This study has 4 parts.

Part 1: Participants aged 12 \< 18 will receive a fixed dose of risankizumab. Part 2: Participants aged 12 \< 18 will receive;

  • Period A: Risankizumab or ustekinumab based on body weight followed by;
  • Period B: Risankizumab or no treatment.
  • Period C: Re-treatment with risankizumab (if needed).

Part 3: Participants aged 6 \< 12 will receive risankizumab based on body weight.

Part 4: Participants aged 6 \< 12 will receive risankizumab based on body weight (Japan only: Participants aged 12 > 18 will receive risankizumab based on body weight).

Around 132 participants will be enrolled in approximately 50 sites worldwide.

Risankizumab and ustekinumab are given as a subcutaneous (under the skin) injection.

Parts 1, 3, and 4: Risankizumab for 40 weeks with a follow-up call 20 weeks later for a study duration of approximately 65 weeks.

Part 2:

  • Period A: Risankizumab or ustekinumab for 16 weeks.
  • Period B: Risankizumab or no treatment for 36 weeks.
  • Period C: Re-treatment with risankizumab for 16 weeks. Follow-up call 20 weeks later for a study duration of approximately 81 weeks. Participants from each Part who meet eligibility criteria for an open-label extension (OLE) study may continue on risankizumab for 216 additional weeks.

There may be a higher burden for study participants compared to standard treatment. Participants will attend monthly visits and medical assessments will check the effect of treatment through blood tests, questionnaires, and checking for side effects.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Plaque Psoriasis
  • Risankizumab
  • Ustekinumab
  • Psoriasis
  • Biologic
  • ABBV-066
  • SKYRIZI
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of chronic plaque psoriasis for at least 6 months before the Baseline Visit.
  • Stable severe or moderate to severe plaque psoriasis as defined in each study part by body surface area (BSA) psoriasis involvement and scores on the Psoriasis Area and Severity Index (PASI) and Static Physician Global Assessment (sPGA).
  • Candidate for systemic therapy as assessed by the investigator and meet the disease activity criteria at both the Screening and Baseline Visits per the protocol.

Exclusion criteria

Exclusion Criteria:

  • Concurrent medical conditions other than the indication being studied or any other reason that the investigator determines would interfere with the participant's participation in this study, would make the participant an unsuitable candidate to receive study drug, or would put the participant at risk by participating in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    Part 1: Risankizumab Dose A

    Participants age 12 to less than 18 receive fixed dose of risankizumab Dose A for 40 weeks.

    Drug: Risankizumab

  • Experimental
    Part 2: Ustekinumab Dose A/B/C then Risankizumab Dose A/B

    Participants age 12 to less than 18 will receive: Period A: Ustekinumab Dose A, Dose B, or Dose C based on body weight for 16 weeks (at Week 0 and Week 4). Period B: Risankizumab Dose A or B based on body weight for 24 weeks.

    Drug: Risankizumab · Drug: Ustekinumab

  • Experimental
    Part 2: Risankizumab Dose A/B

    Participants age 12 to less than 18 will receive: Period A: Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4). Period B: Participants who respond to Risankizumab in Period A are re-randomized to continue Risankizumab Dose A or B based on body weight for up to 24 weeks or withdraw from treatment until flare. Period C: Participants withdrawn from treatment in Period B and experience a flare in symptoms at Week 28 or beyond are eligible for re-treatment with Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4).

    Drug: Risankizumab

  • Experimental
    Part 3: Risankizumab Dose A/B

    Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks.

    Drug: Risankizumab

  • Experimental
    Part 4: Risankizumab Dose A/B

    Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks (Japan only: participants age 12 to less than 18 years will be included).

    Drug: Risankizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 (Defined as at Least 75% Improvement in PASI)

    The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 75% improvement in PASI.

    Time frame: Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)

  2. Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1)

    The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).

    Time frame: At Week 16 of initial treatment in each part of the study (Parts 1-4)

  3. Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1) and With at Least 2 Grade Improvement From Baseline

    The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).

    Time frame: Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)

Secondary outcomes

  1. Percentage of Participants Achieving PASI 90 (Defined as at Least 90% Improvement in PASI)

    The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 90% improvement in PASI.

    Time frame: Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)

  2. Percentage of Participants Achieving PASI 100 (Defined as at Least 100% Improvement in PASI)

    The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 100% improvement in PASI.

    Time frame: Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)

  3. Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (0 or 1)

    The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).

    Time frame: Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)

  4. Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1) and With at Least 2 Grade Improvement From Baseline

    The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).

    Time frame: Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)

  5. Percentage of Participants Achieving PASI 50 (Defined as at Least 50% Improvement in PASI)

    The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 50% improvement in PASI.

    Time frame: Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)

  6. Percentage of Participants Achieving PASI 50 (Defined as at Least 50% Improvement in PASI)

    The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 50% improvement in PASI.

    Time frame: Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)

  7. Percentage of Participants Achieving PASI 90 (Defined as at Least 90% Improvement in PASI)

    The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 90% improvement in PASI.

    Time frame: Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)

  8. Percentage of Participants Achieving PASI 100 (Defined as at Least 100% Improvement in PASI)

    The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 100% improvement in PASI.

    Time frame: Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)

  9. Percentage of Participants Achieving PASI 75 (Defined as at Least 75% Improvement in PASI)

    The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 75% improvement in PASI.

    Time frame: Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)

  10. Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score

    The CDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on quality of life (QOL). The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item was scored on a 4-point scale: 0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.

    Time frame: Baseline (Week 0) to Week 16 of initial treatment in Part 2 (Period A)

  11. Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score

    The CDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on quality of life (QOL). The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item was scored on a 4-point scale: 0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.

    Time frame: Baseline (Week 0) to Week 16 of the re-treatment phase in Part 2 (Period C)

  12. Change From Baseline in Family Dermatology Life Quality Index (FDLQI) Total Score

    The FDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on Quality of Life (QOL) of family members. It consists of 10 questions that assess the impact of skin diseases on different aspects of the family member's QOL. Each item was scored on a 4-point scale: 0 = not at all; 1 = a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.

    Time frame: Baseline (Week 0) to Week 16 of initial treatment in Part 2 (Period A)

  13. Change From Baseline in Family Dermatology Life Quality Index (FDLQI) Total Score

    The FDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on Quality of Life (QOL) of family members. It consists of 10 questions that assess the impact of skin diseases on different aspects of the family member's QOL. Each item was scored on a 4-point scale: 0 = not at all; 1 = a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.

    Time frame: Baseline (Week 0) to Week 16 of the re-treatment phase in Part 2 (Period C)

  14. Change From Baseline in Itch Numerical Rating Scale (Itch NRS)

    The itch NRS is an 11-point scale that participants complete to describe the intensity of their itch. The itch NRS scale scores varies between 0, representing "no itching" and 10, representing "worst itch imaginable" with higher scores representing worse outcomes. A negative change from baseline indicates less intense itching and better outcomes.

    Time frame: Baseline (Week 0) to Week 16 of initial treatment in Part 2 (Period A)

  15. Change From Baseline in Itch Numerical Rating Scale (Itch NRS)

    The itch NRS is an 11-point scale that participants complete to describe the intensity of their itch. The itch NRS scale scores varies between 0, representing "no itching" and 10, representing "worst itch imaginable" with higher scores representing worse outcomes. A negative change from baseline indicates less intense itching and better outcomes.

    Time frame: Baseline (Week 0) to Week 16 of the re-treatment phase in Part 2 (Period C)

  16. Percentage of Participants Achieving >= 4-point Improvement in the Itch Numerical Rating Scale (in Participants With Baseline Score >= 4)

    The itch NRS is an 11-point scale that participants complete to describe the intensity of their itch within a 24-hour recall period. The itch NRS scale scores varies between 0, representing "no itching" and 10, representing "worst itch imaginable" with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving \>= 4 point improvement in the itch NRS in participants with a baseline itch NRS score of \>=4.

    Time frame: Baseline (Week 0) to Week 16 of initial treatment in Part 2 (Period A)

07

Results

Posted May 20, 2025

Participant flow

Part 1 (Baseline to Week 40)
Participant flow — Part 1 (Baseline to Week 40)
MilestonePart 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 2 Period A: Ustekinumab; Period B: RisankizumabPart 2 Period A Risankizumab Non-responders; Period B: RisankizumabPart 2 Period A Risankizumab Responders; Period B: RisankizumabPart 2 Period A Risankizumab Responders; Period B: Treatment WithdrawalPart 2 Period C: RisankizumabPart 3: RisankizumabPart 4: Risankizumab
Started12000000000
Completed12000000000
Not completed0000000000
Part 2: Period A (Baseline to Week 16)
Participant flow — Part 2: Period A (Baseline to Week 16)
MilestonePart 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 2 Period A: Ustekinumab; Period B: RisankizumabPart 2 Period A Risankizumab Non-responders; Period B: RisankizumabPart 2 Period A Risankizumab Responders; Period B: RisankizumabPart 2 Period A Risankizumab Responders; Period B: Treatment WithdrawalPart 2 Period C: RisankizumabPart 3: RisankizumabPart 4: Risankizumab
Started028540000000
Completed028530000000
Not completed0010000000
Withdrew: Lost to follow-up0010000000
Part 2: Period B (Week 16 to Week 52)
Participant flow — Part 2: Period B (Week 16 to Week 52)
MilestonePart 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 2 Period A: Ustekinumab; Period B: RisankizumabPart 2 Period A Risankizumab Non-responders; Period B: RisankizumabPart 2 Period A Risankizumab Responders; Period B: RisankizumabPart 2 Period A Risankizumab Responders; Period B: Treatment WithdrawalPart 2 Period C: RisankizumabPart 3: RisankizumabPart 4: Risankizumab
Started00028102221000
Completed00028102221000
Not completed0000000000
Part 2: Period C (Week 52 to Week 68)
Participant flow — Part 2: Period C (Week 52 to Week 68)
MilestonePart 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 2 Period A: Ustekinumab; Period B: RisankizumabPart 2 Period A Risankizumab Non-responders; Period B: RisankizumabPart 2 Period A Risankizumab Responders; Period B: RisankizumabPart 2 Period A Risankizumab Responders; Period B: Treatment WithdrawalPart 2 Period C: RisankizumabPart 3: RisankizumabPart 4: Risankizumab
Started0000000800
Completed0000000800
Not completed0000000000
Part 3 (Baseline to Week 52)
Participant flow — Part 3 (Baseline to Week 52)
MilestonePart 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 2 Period A: Ustekinumab; Period B: RisankizumabPart 2 Period A Risankizumab Non-responders; Period B: RisankizumabPart 2 Period A Risankizumab Responders; Period B: RisankizumabPart 2 Period A Risankizumab Responders; Period B: Treatment WithdrawalPart 2 Period C: RisankizumabPart 3: RisankizumabPart 4: Risankizumab
Started00000000130
Completed00000000130
Not completed0000000000
Part 4 (Baseline to Week 52)
Participant flow — Part 4 (Baseline to Week 52)
MilestonePart 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 2 Period A: Ustekinumab; Period B: RisankizumabPart 2 Period A Risankizumab Non-responders; Period B: RisankizumabPart 2 Period A Risankizumab Responders; Period B: RisankizumabPart 2 Period A Risankizumab Responders; Period B: Treatment WithdrawalPart 2 Period C: RisankizumabPart 3: RisankizumabPart 4: Risankizumab
Started00000000032
Completed00000000029
Not completed0000000003
Withdrew: Withdrawal by subject0000000001
Withdrew: Lost to follow-up0000000001
Withdrew: Other than specified0000000001

Outcome measures

PrimaryPercentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 (Defined as at Least 75% Improvement in PASI)

The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 75% improvement in PASI.

Time frame:
Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 (Defined as at Least 75% Improvement in PASI)
percentage of participantsPart 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 3: RisankizumabPart 4: Risankizumab
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 (Defined as at Least 75% Improvement in PASI)83.3 (51.6 to 97.9)85.7 (67.3 to 96.0)85.2 (72.9 to 93.4)92.3 (64.0 to 99.8)86.7 (69.3 to 96.2)
PrimaryPercentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1)

The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).

Time frame:
At Week 16 of initial treatment in each part of the study (Parts 1-4)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1)
percentage of participantsPart 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 3: RisankizumabPart 4: Risankizumab
Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1)83.3 (51.6 to 97.9)75.0 (55.1 to 89.3)79.6 (66.5 to 89.4)84.6 (54.6 to 98.1)90.0 (73.5 to 97.9)
PrimaryPercentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1) and With at Least 2 Grade Improvement From Baseline

The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).

Time frame:
Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1) and With at Least 2 Grade Improvement From Baseline
percentage of participantsPart 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 3: RisankizumabPart 4: Risankizumab
Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1) and With at Least 2 Grade Improvement From Baseline83.3 (51.6 to 97.9)67.9 (47.6 to 84.1)68.5 (54.4 to 80.5)84.6 (54.6 to 98.1)83.3 (65.3 to 94.4)
SecondaryPercentage of Participants Achieving PASI 90 (Defined as at Least 90% Improvement in PASI)

The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 90% improvement in PASI.

Time frame:
Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 90 (Defined as at Least 90% Improvement in PASI)
percentage of participantsPart 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 3: RisankizumabPart 4: Risankizumab
Percentage of Participants Achieving PASI 90 (Defined as at Least 90% Improvement in PASI)83.3 (51.6 to 97.9)60.7 (40.6 to 78.5)64.8 (50.6 to 77.3)84.6 (54.6 to 98.1)76.7 (57.7 to 90.1)
SecondaryPercentage of Participants Achieving PASI 100 (Defined as at Least 100% Improvement in PASI)

The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 100% improvement in PASI.

Time frame:
Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 100 (Defined as at Least 100% Improvement in PASI)
percentage of participantsPart 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 3: RisankizumabPart 4: Risankizumab
Percentage of Participants Achieving PASI 100 (Defined as at Least 100% Improvement in PASI)41.7 (15.2 to 72.3)17.9 (6.1 to 36.9)40.7 (27.6 to 55.0)53.8 (25.1 to 80.8)43.3 (25.5 to 62.6)
SecondaryPercentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (0 or 1)

The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).

Time frame:
Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (0 or 1)
percentage of participantsPart 2 Period C: Risankizumab
Baseline (Week 0)12.5 (0.3 to 52.7)
Week 1662.5 (24.5 to 91.5)
SecondaryPercentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1) and With at Least 2 Grade Improvement From Baseline

The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).

Time frame:
Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1) and With at Least 2 Grade Improvement From Baseline
percentage of participantsPart 2 Period C: Risankizumab
Baseline (Week 0)0.0 (0.0 to 36.9)
Week 1662.5 (24.5 to 91.5)
SecondaryPercentage of Participants Achieving PASI 50 (Defined as at Least 50% Improvement in PASI)

The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 50% improvement in PASI.

Time frame:
Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 50 (Defined as at Least 50% Improvement in PASI)
percentage of participantsPart 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 3: RisankizumabPart 4: Risankizumab
Percentage of Participants Achieving PASI 50 (Defined as at Least 50% Improvement in PASI)91.7 (61.5 to 99.8)92.9 (76.5 to 99.1)90.7 (79.7 to 96.9)100 (75.3 to 100.0)96.7 (82.8 to 99.9)
SecondaryPercentage of Participants Achieving PASI 50 (Defined as at Least 50% Improvement in PASI)

The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 50% improvement in PASI.

Time frame:
Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 50 (Defined as at Least 50% Improvement in PASI)
percentage of participantsPart 2 Period C: Risankizumab
Baseline (Week 0)75.0 (34.9 to 96.8)
Week 1687.5 (47.3 to 99.7)
SecondaryPercentage of Participants Achieving PASI 90 (Defined as at Least 90% Improvement in PASI)

The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 90% improvement in PASI.

Time frame:
Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 90 (Defined as at Least 90% Improvement in PASI)
percentage of participantsPart 2 Period C: Risankizumab
Baseline (Week 0)37.5 (8.5 to 75.5)
Week 1687.5 (47.3 to 99.7)
SecondaryPercentage of Participants Achieving PASI 100 (Defined as at Least 100% Improvement in PASI)

The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 100% improvement in PASI.

Time frame:
Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 100 (Defined as at Least 100% Improvement in PASI)
percentage of participantsPart 2 Period C: Risankizumab
Baseline (Week 0)0 (0.0 to 36.9)
Week 1625.0 (3.2 to 65.1)
SecondaryPercentage of Participants Achieving PASI 75 (Defined as at Least 75% Improvement in PASI)

The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 75% improvement in PASI.

Time frame:
Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 75 (Defined as at Least 75% Improvement in PASI)
percentage of participantsPart 2 Period C: Risankizumab
Baseline (Week 0)37.5 (8.5 to 75.5)
Week 1687.5 (47.3 to 99.7)
SecondaryChange From Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score

The CDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on quality of life (QOL). The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item was scored on a 4-point scale: 0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.

Time frame:
Baseline (Week 0) to Week 16 of initial treatment in Part 2 (Period A)
Reported as:
Least squares mean · score on a scale
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score
score on a scalePart 2 Period A: UstekinumabPart 2 Period A: Risankizumab
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score-6.8 ± 0.66-7.4 ± 0.49
SecondaryChange From Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score

The CDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on quality of life (QOL). The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item was scored on a 4-point scale: 0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.

Time frame:
Baseline (Week 0) to Week 16 of the re-treatment phase in Part 2 (Period C)
Reported as:
Least squares mean · score on a scale
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score
score on a scalePart 2 Period C: Risankizumab
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score-7.5 ± 2.88
SecondaryChange From Baseline in Family Dermatology Life Quality Index (FDLQI) Total Score

The FDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on Quality of Life (QOL) of family members. It consists of 10 questions that assess the impact of skin diseases on different aspects of the family member's QOL. Each item was scored on a 4-point scale: 0 = not at all; 1 = a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.

Time frame:
Baseline (Week 0) to Week 16 of initial treatment in Part 2 (Period A)
Reported as:
Least squares mean · score on a scale
Change From Baseline in Family Dermatology Life Quality Index (FDLQI) Total Score
score on a scalePart 2 Period A: UstekinumabPart 2 Period A: Risankizumab
Change From Baseline in Family Dermatology Life Quality Index (FDLQI) Total Score-6.0 ± 0.84-6.9 ± 0.60
SecondaryChange From Baseline in Family Dermatology Life Quality Index (FDLQI) Total Score

The FDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on Quality of Life (QOL) of family members. It consists of 10 questions that assess the impact of skin diseases on different aspects of the family member's QOL. Each item was scored on a 4-point scale: 0 = not at all; 1 = a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.

Time frame:
Baseline (Week 0) to Week 16 of the re-treatment phase in Part 2 (Period C)
Reported as:
Least squares mean · score on a scale
Change From Baseline in Family Dermatology Life Quality Index (FDLQI) Total Score
score on a scalePart 2 Period C: Risankizumab
Change From Baseline in Family Dermatology Life Quality Index (FDLQI) Total Score-5.8 ± 3.29
SecondaryChange From Baseline in Itch Numerical Rating Scale (Itch NRS)

The itch NRS is an 11-point scale that participants complete to describe the intensity of their itch. The itch NRS scale scores varies between 0, representing "no itching" and 10, representing "worst itch imaginable" with higher scores representing worse outcomes. A negative change from baseline indicates less intense itching and better outcomes.

Time frame:
Baseline (Week 0) to Week 16 of initial treatment in Part 2 (Period A)
Reported as:
Least squares mean · score on a scale
Change From Baseline in Itch Numerical Rating Scale (Itch NRS)
score on a scalePart 2 Period A: UstekinumabPart 2 Period A: Risankizumab
Change From Baseline in Itch Numerical Rating Scale (Itch NRS)-2.9 ± 0.50-3.8 ± 0.38
SecondaryChange From Baseline in Itch Numerical Rating Scale (Itch NRS)

The itch NRS is an 11-point scale that participants complete to describe the intensity of their itch. The itch NRS scale scores varies between 0, representing "no itching" and 10, representing "worst itch imaginable" with higher scores representing worse outcomes. A negative change from baseline indicates less intense itching and better outcomes.

Time frame:
Baseline (Week 0) to Week 16 of the re-treatment phase in Part 2 (Period C)
Reported as:
Least squares mean · score on a scale
Change From Baseline in Itch Numerical Rating Scale (Itch NRS)
score on a scalePart 2 Period C: Risankizumab
Change From Baseline in Itch Numerical Rating Scale (Itch NRS)-2.8 ± 1.68
SecondaryPercentage of Participants Achieving >= 4-point Improvement in the Itch Numerical Rating Scale (in Participants With Baseline Score >= 4)

The itch NRS is an 11-point scale that participants complete to describe the intensity of their itch within a 24-hour recall period. The itch NRS scale scores varies between 0, representing "no itching" and 10, representing "worst itch imaginable" with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving \>= 4 point improvement in the itch NRS in participants with a baseline itch NRS score of \>=4.

Time frame:
Baseline (Week 0) to Week 16 of initial treatment in Part 2 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving >= 4-point Improvement in the Itch Numerical Rating Scale (in Participants With Baseline Score >= 4)
percentage of participantsPart 2 Period A: UstekinumabPart 2 Period A: Risankizumab
Percentage of Participants Achieving >= 4-point Improvement in the Itch Numerical Rating Scale (in Participants With Baseline Score >= 4)57.1 (28.9 to 82.3)64.9 (47.5 to 79.8)

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from the start of safety data collection (Day 1) to the end of the study follow-up. The median time on follow-up was 385.5, 132.5, 130.5, 255.5, 252.0, 256.5, 250.0, 119.5, 385.0, and 386.0 days for arms Part 1: Risankizumab (Risa), Part 2 Period A (P2PA): Risa, P2PA: Ustekinumab (Uste), P2PB: Uste/Risa, P2PB Non-responders/Risa, P2PB Responders/Risa, P2PB Treatment Withdrawal, P2PC: Risa, P3: Risa, and P4: Risa respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Risankizumab0/12 (0%)0/12 (0%)6/12 (50%)
Part 2 Period A: Risankizumab0/54 (0%)0/54 (0%)21/54 (38.9%)
Part 2 Period A: Ustekinumab0/28 (0%)0/28 (0%)11/28 (39.3%)
Part 2 Period A: Ustekinumab; Period B: Risankizumab0/28 (0%)1/28 (3.6%)19/28 (67.9%)
Part 2 Period A Risankizumab Non-responders; Period B: Risankizumab0/10 (0%)1/10 (10%)8/10 (80%)
Part 2 Period A Risankizumab Responders; Period B: Risankizumab0/22 (0%)0/22 (0%)13/22 (59.1%)
Part 2 Period A Risankizumab Responders; Period B: Treatment Withdrawal0/21 (0%)1/21 (4.8%)11/21 (52.4%)
Part 2 Period C: Risankizumab0/8 (0%)0/8 (0%)4/8 (50%)
Part 3: Risankizumab0/13 (0%)0/13 (0%)6/13 (46.2%)
Part 4: Risankizumab0/32 (0%)0/32 (0%)23/32 (71.9%)
Most frequent serious events
Most frequent serious events
EventPart 1: RisankizumabPart 2 Period A: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: Ustekinumab; Period B: RisankizumabPart 2 Period A Risankizumab Non-responders; Period B: RisankizumabPart 2 Period A Risankizumab Responders; Period B: RisankizumabPart 2 Period A Risankizumab Responders; Period B: Treatment WithdrawalPart 2 Period C: RisankizumabPart 3: RisankizumabPart 4: Risankizumab
FIBULA FRACTUREInjury, poisoning and procedural complications0/120/540/280/281/100/220/210/80/130/32
EOSINOPHILIC OESOPHAGITISGastrointestinal disorders0/120/540/280/280/100/221/210/80/130/32
SUICIDAL IDEATIONPsychiatric disorders0/120/540/281/280/100/220/210/80/130/32
Most frequent other events
Showing 10 of 46
Most frequent other events
EventPart 1: RisankizumabPart 2 Period A: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: Ustekinumab; Period B: RisankizumabPart 2 Period A Risankizumab Non-responders; Period B: RisankizumabPart 2 Period A Risankizumab Responders; Period B: RisankizumabPart 2 Period A Risankizumab Responders; Period B: Treatment WithdrawalPart 2 Period C: RisankizumabPart 3: RisankizumabPart 4: Risankizumab
NASOPHARYNGITISInfections and infestations0/1210/544/2812/284/105/222/210/81/1310/32
PYREXIAGeneral disorders2/120/540/282/280/100/220/212/81/134/32
COVID-19Infections and infestations1/125/542/281/282/101/222/210/81/130/32
HEADACHENervous system disorders2/123/543/283/280/104/221/210/80/131/32
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations1/121/540/281/281/102/221/210/82/131/32
COUGHRespiratory, thoracic and mediastinal disorders0/121/540/283/281/101/221/210/82/133/32
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders0/121/540/281/280/100/223/210/80/130/32
SKIN PAPILLOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/120/540/280/280/103/220/210/80/132/32
CHILLSGeneral disorders1/120/540/281/280/100/220/211/80/130/32
BACTERIAL VAGINOSISInfections and infestations0/120/540/280/280/100/220/211/80/130/32

Baseline characteristics

The Intent to Treat (ITT) Population included all enrolled participants in from Parts 1, 3, and 4, and all randomized participants from Part 2.

Age, Customized
Age, Customized(Participants)Part 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 3: RisankizumabPart 4: RisankizumabTotal
6 to < 9 years00031013
9 to < 12 years000102030
12 to <15 years514220041
15 to <18 years714320053
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 3: RisankizumabPart 4: RisankizumabTotal
Female7153191880
Male5132341257
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 3: RisankizumabPart 4: RisankizumabTotal
Hispanic or Latino2681017
Not Hispanic or Latino1022461230120
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 3: RisankizumabPart 4: RisankizumabTotal
American Indian or Alaska Native000011
Asian1623719
Native Hawaiian or Other Pacific Islander100001
Black or African American213028
White620481020104
More than one race211004
Unknown or Not Reported000000
Psoriasis Area and Severity Index (PASI) Score
Psoriasis Area and Severity Index (PASI) Score(score on a scale)Part 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 3: RisankizumabPart 4: RisankizumabTotal
Mean21.43 ± 8.12416.55 ± 7.22916.39 ± 4.90926.21 ± 9.15818.59 ± 9.21118.28 ± 7.716
Static Physician Global Assessment (sPGA) Category
Static Physician Global Assessment (sPGA) Category(Participants)Part 1: RisankizumabPart 2 Period A: UstekinumabPart 2 Period A: RisankizumabPart 3: RisankizumabPart 4: RisankizumabTotal
0000000
1000000
20260311
30254222392
4121611434
08

Study locations

53 sites
  • UAB Department of Dermatology /ID# 218834
    Birmingham, Alabama 35233, United States
  • First OC Dermatology /ID# 217733
    Fountain Valley, California 92708, United States
  • Integrative Skin Science and Research /ID# 221741
    Sacramento, California 95815, United States
  • University of California San Diego - Rady Children's Hospital San Diego /ID# 217906
    San Diego, California 92123, United States
  • Rybear, Inc /ID# 223164
    Fort Lauderdale, Florida 33316-1952, United States
  • Solutions Through Adv Rch /ID# 217936
    Jacksonville, Florida 32256, United States
  • Olympian Clinical Research- St. Petersburg /ID# 217941
    Saint Petersburg, Florida 33709-1405, United States
  • Advanced Clinical Research Institute /ID# 222706
    Tampa, Florida 33607, United States
  • University Dermatology and Vein Clinic, LLC /ID# 222778
    Darien, Illinois 60561, United States
  • Duplicate_Arlington Dermatology /ID# 217472
    Rolling Meadows, Illinois 60008, United States
  • Duplicate_Skin Cancer and Dermatology Institute (SCDI) /ID# 221738
    Reno, Nevada 89052, United States
  • Duplicate_Forest Hills Dermatology Group /ID# 227941
    Kew Gardens, New York 11415, United States
  • Univ Hosp Cleveland /ID# 228483
    Cleveland, Ohio 44106, United States
  • The Ohio State University /ID# 217808
    Columbus, Ohio 43210, United States
  • Apex Clinical Research Center /ID# 228537
    Mayfield Heights, Ohio 44124, United States
  • Vital Prospects Clinical Research Institute, PC /ID# 217960
    Tulsa, Oklahoma 74136-7049, United States
  • Medical University of South Carolina /ID# 217735
    Charleston, South Carolina 29425, United States
  • Arlington Research Center, Inc /ID# 217471
    Arlington, Texas 76011, United States
  • West Virginia University Hospitals /ID# 228352
    Morgantown, West Virginia 26506, United States
  • Clinical Investigation Specialist, Inc - Kenosha /ID# 223161
    Kenosha, Wisconsin 53144-1782, United States
  • Wisconsin Medical Center /ID# 240005
    Milwaukee, Wisconsin 53226, United States
  • Duplicate_Dermatology Research Institute Inc. /ID# 226172
    Calgary, Alberta T2J 7E1, Canada
  • Karma Clinical Trials /ID# 226177
    St. John's, Newfoundland and Labrador A1A 4Y3, Canada
  • Hospital for Sick Children /ID# 226167
    Toronto, Ontario M5G 1X8, Canada
  • CHU Sainte-Justine /ID# 226170
    Montreal, Quebec H3T 1C5, Canada
  • Fachklinik Bad Bentheim /ID# 226014
    Bad Bentheim, Niedersachsen 48455, Germany
  • Universitaetsklinikum Bonn /ID# 228880
    Bonn, Nordrhein-Westfalen 53127, Germany
  • Universitaetsklinikum Muenster /ID# 225988
    Muenster, Nordrhein-Westfalen 48149, Germany
  • Duplicate_Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz /ID# 225987
    Mainz, Rheinland-Pfalz 55131, Germany
  • Universitaetsklinikum Carl Gustav Carus Dresden /ID# 228881
    Dresden, Sachsen 01307, Germany
  • Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 226013
    Kiel, Schleswig-Holstein 24105, Germany
  • Nagoya City University Hospital /ID# 230830
    Nagoya shi, Aichi 467-8602, Japan
  • Hiroshima University Hospital /ID# 256162
    Hiroshima-shi, Hiroshima 734-8551, Japan
  • Mie University Hospital /ID# 230836
    Tsu-shi, Mie 514-8507, Japan
  • Kansai Medical University Hospital /ID# 231215
    Hirakata-shi, Osaka 573-1191, Japan
  • Duplicate_Teikyo University Hospital /ID# 255188
    Itabashi-ku, Tokyo 173-8606, Japan
  • Tokyo Medical University Hospital /ID# 230575
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Dermed Centrum Medyczne Sp. z o.o /ID# 226062
    Lodz, Lodzkie 90-265, Poland
  • Dermoklinika Centrum Medyczne s.c. /ID# 226063
    Lodz, Lodzkie 90-436, Poland
  • High-Med Przychodnia Specjalistyczna /ID# 226060
    Warszawa, Mazowieckie 01-817, Poland
  • Uniwersytecki Szpital Kliniczny im. F. Chopina w Rzeszowie /ID# 226116
    Rzeszow, Podkarpackie 35-055, Poland
  • Centrum Badan Klinicznych PI-House sp. z o.o. /ID# 228252
    Gdansk, Pomorskie 80-546, Poland
  • Hospital Sant Joan de Deu /ID# 225722
    Esplugues de Llobregat, Barcelona 08950, Spain
  • Hospital General Universitario Gregorio Maranon /ID# 225721
    Madrid, 28007, Spain
  • Hospital Universitario Infanta Leonor /ID# 225720
    Madrid, 28031, Spain
  • Hospital Universitario 12 de Octubre /ID# 227860
    Madrid, 28041, Spain
  • Complejo Hospitalario Universitario de Pontevedra /ID# 226061
    Pontevedra, 36071, Spain
  • Duplicate_Royal Devon University Healthcare NHS Foundation Trust /ID# 228078
    Exeter, Devon EX2 5DW, United Kingdom
  • Duplicate_University Hospital Plymouth NHS Trust /ID# 227230
    Plymouth, Devon PL6 5FP, United Kingdom
  • Guys and St Thomas NHS Foundation Trust /ID# 227224
    London, Greater London SE1 9RT, United Kingdom
  • Chelsea and Westminster Hospital /ID# 227231
    London, Greater London SW10 9NH, United Kingdom
  • NHS Greater Glasgow and Clyde /ID# 227226
    Glasgow, Scotland G12 0XH, United Kingdom
  • Frimley Health NHS Foundation Trust /ID# 229525
    Camberley, Surrey GU16 7UJ, United Kingdom
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Feb 2024, 42 months.

Results were first posted in May 2025, 1 year 3 months after primary completion. A results delay was requested in Jan 2025.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 42 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2020
First posted
Jun 17, 2020
StartActual
Jul 14, 2020
Primary completionActual
Feb 12, 2024
CompletionActual
Oct 15, 2024
Results delay requested
Jan 9, 2025
Results first posted
May 20, 2025
Last update
May 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04435600
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 17, 2020
Start date
Jul 14, 2020
Primary completion
Feb 12, 2024
Completion
Oct 15, 2024
Results posted
May 20, 2025
Last update
May 20, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion